HealthCare Global Enterprises Limited (HCG) Earnings Call Transcript & Summary

November 6, 2026

National Stock Exchange of India IN Health Care Health Care Providers and Services earnings 52 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and welcome to the Healthcare Global Enterprises Limited earnings conference call. <<operator_script>> Kindly be aware that this call is being recorded. At this point, I'll turn things over to Mr. Anoop Poojari of CDR India. Thank you, and the floor is yours, sir.

Anoop Poojari

unknown
#2

Thanks a lot. Good afternoon, everybody, and we appreciate your presence on the Healthcare Global Enterprises Q2 and H1 FY 2027 Earnings Conference Call. Joining us today are Dr. Manish Mattoo, Executive Director and CEO of the company; Mr. Sanjeev Kumar, Chief Financial Officer; and Mr. Ravi Gothwal, Head of Investor Relations. We'd like to kick things off with opening remarks from Manish, and after that we'll open the floor for an interactive question-and-answer session. Before we get going, I want to note that certain statements on today's call might be forward-looking in nature, and a disclaimer to that effect has been included in the earnings presentation shared with you earlier. I'd now like to invite Manish to deliver his opening remarks.

Manish Mattoo

executive
#3

Thank you, Anoop. Good afternoon, everyone, and thanks for being with us on HCG's Quarter 2 and H1 FY '27 earnings call. I'm happy to report that our growth momentum carried through into the second quarter, helped by healthy patient demand, an improving revenue mix, and steady progress on our strategic and operational priorities. As we noted on our last earnings call, our strategic priorities are still focused on profitable growth, better asset utilization, stronger clinical differentiation, and optimizing our revenue mix. We're encouraged by what was achieved during the quarter in all of these areas. Turning to our financial performance, I'd like to point out that every financial figure presented today excludes the Milann fertility business, which was divested in June 2026. The comparable prior year figures have been adjusted as well, so the comparison is like-for-like. In quarter 2 FY '27, HCG delivered revenue of INR 7,318 million, a rise of 16% year-on-year. Leaving out our North Bangalore new hospital, revenue growth was 14% year-on-year. Growth was broad-based across our operating clusters, driven mainly by a 9% increase in patient volumes, while average revenue per patient rose 7% year-on-year. The gain in ARPP was supported by a favorable payer mix and a growing contribution from high complexity oncology treatments.

Manish Mattoo

executive
#4

That figure covers a 37% rise in robotic surgeries versus the prior year, together with widening uptake of other advanced therapies and surgical procedures throughout our network. As we've said consistently, our aim isn't just to push patient volumes higher — it's to lift both the quantity and the quality of our revenues by drawing a bigger contribution from complex oncology procedures, along with a better payer mix, stronger clinical outcomes and greater productivity throughout our specialized oncology ecosystem. Consistent with that strategy, we keep concentrating on growing our noninstitutional business while steadily optimizing how much exposure we carry to lower realization segments. Those efforts are producing encouraging results: non-institutional revenue is up 21% year-on-year, which lifted its revenue share by more than 300 basis points, to 69%. Turning to profitability, EBITDA for the quarter came to INR 1,425 million, and that includes the North Bangalore loss of INR 61 million — a 17% year-on-year increase, with EBITDA margins rising to 19.7% from 19.2% in quarter 2 of last financial year. Although we keep benefiting from better revenue quality and operating efficiencies, margin expansion in the quarter was partly held back by roughly INR 60 million of incremental employee costs tied to the revision in Karnataka Wage Act 2026.

Manish Mattoo

executive
#5

When you strip things down to a like-for-like comparison and leave out the wage revision effect, EBITDA rose by more than 20% versus the prior year. At North Bangalore, which is our most recently opened hospital, we kept seeing solid improvement, and its EBITDA loss narrowed to INR 61 million in this quarter. We remain focused on speeding up the clinical ramp-up, raising capacity utilization, and steadily cutting operating losses. Now I'll walk you through how each of our operating clusters performed. To begin with the South cluster. Revenue came in at INR 2,941 million, a robust 18% increase, and that cluster accounted for 40% of our total revenue. The growth reflected a 14% gain in ARPP and a 4% rise in patient volumes, with a big contribution from our Bangalore Center of Excellence and the ongoing ramp-up of the North Bangalore hospital. ARPP gains in that cluster were further helped by a favorable payer mix and a greater share of high-end procedures and therapies. Turning to the West cluster. Revenue reached INR 3,147 million, up 10% from a year earlier, and contributed 43% of total revenue. The main driver was a 7% growth in patient volumes, while ARPP rose 3%, helped by a favorable payer mix. Maharashtra put in a strong showing with mid-teens growth, powered by healthy patient demand and better realization, led by a shift toward a favorable payer mix.

Manish Mattoo

executive
#6

That was partly counterbalanced by fairly modest expansion at our Gujarat sites, mostly because we intentionally adjusted the institutional case mix in order to lift profitability. Now for the East cluster. Revenue came in at INR 928 million, up 23% year-on-year, and accounted for 11% of our total revenue. The increase was driven by patient volumes rising 18%, with ARPP climbing 5% year-on-year. Growth was spread broadly throughout the region, with Ranchi delivering a particularly strong performance. At our international Kenya operations, revenue reached INR 302 million, posting roughly 54% year-on-year growth for the quarter. Results benefited from stronger patient inflows in radiation oncology, helped by the installation of a new radiation therapy machine, along with higher medical oncology therapies after 13 new beds were added. I'd also like to point to several key developments from the quarter. In Q2 FY '27, we added 25 operational beds throughout our network — 13 beds in Kenya, 7 beds in Kolkata and 5 beds at Nagpur. Those additions bring us to a total of 146 beds operationalized in H1 FY '27, which further reinforces capacity at both existing and newer facilities. In addition to expanding capacity, we keep investing in advanced medical technologies.

Manish Mattoo

executive
#7

This quarter, we put into service the MR Linac — a very sophisticated adaptive radiation therapy platform — at our North Bangalore Hospital, and we also installed a cardiac surgical robotic system at our multi-specialty hospital in Ahmedabad, which further reinforces our technology-driven treatment capabilities. Clinically speaking, notable milestones encompassed the first CAR-T cell therapy performed at HCC Ahmedabad, the rollout of a robotic breast surgical system at KR Road Bangalore, robotic spine surgery at HCG Rajkot, and transoral robotic surgery at HCG Baroda. In addition, we brought out a 1,212 gene liquid biopsy panel and added two new nuclear medicine tracers at KR Hospital Bangalore, which sharpens our precision diagnostics offering. Our clinical know-how also shows up in a number of complex cases handled throughout our network. Among them were a limb-saving operation on a 28-day old infant, precision radiosurgery with CyberKnife to shrink a tumor and trace around the optic nerve with no vision loss whatsoever, and complicated shoulder tumor reconstruction relying on customized 3D-printed titanium implants. Such cases show how we bring together multidisciplinary expertise and advanced technologies to treat complex cancers while keeping organ preservation and patient outcomes front of mind. Finally, I want to touch briefly on the latest regulatory developments regarding trade margins on nonscheduled anticancer drugs. We understand how important it is to make cancer treatment more affordable and accessible.

Manish Mattoo

executive
#8

That fits with HCG's philosophy of getting cancer treatment right on the first attempt, a philosophy that stresses high-quality, comprehensive cancer care with clinical outcomes as good as they can be. The regulatory steps cover a particular subset of oncology drugs, and their effects differ according to the drug portfolio, pricing arrangements and payer mix. From our assessment on an absolute basis, we estimate an annualized impact to EBITDA in the mid- to high single-digit percentage range. Although we expect some near-term effect as the regulatory framework comes into force, we stay confident about the strength of our underlying growth drivers. Growing cancer incidents, together with better screening and affordability, continue to support sustained demand for high-quality cancer care. We stay focused on serving this opportunity through continued growth in patient volumes, improved asset utilization, revenue mix optimization and identified operational improvement levers across our network. We believe these initiatives will support sustainable long-term growth and value creation for our stakeholders. With that, I would like to hand the call over to Sanjeev, who will briefly take us through our H1 FY '27 financial performance, after which we will open the floor for questions. Thank you, everyone. Yes. Thank you.

Sanjeev Kumar

executive
#9

Thanks, Manish. Good afternoon, everyone. I'll walk you through how we performed financially in the first half of FY '27, and I'll also give you an update on the balance sheet. We turned in healthy financial results in the first half, helped by revenue growth, better quality of revenue, and operating efficiencies. Consolidated revenue for H1 FY '27 came to INR 14,100 million, which works out to 15% growth on a year-on-year basis. That top-line increase was powered by a 9% rise in patient volume together with 6% growth in ARPP. The ARPP improvement came mainly from a favorable payer mix and a growing contribution from high-end procedures, robotic surgeries among them. Adjusted EBITDA for H1 FY '27 was INR 2,740 million, up 18% on a year-on-year basis. Adjusted EBITDA margin rose 84 basis points to 19.7%, versus 18.8% in H1 FY '26, which reflects continued gains in the quality of revenue and in operating efficiencies. In the quarter, we also booked an ESOP expense of INR 29.8 million stemming from the ESOPs granted in September 2026. Keep in mind that this expense is noncash. Turning now to other financial items: depreciation and amortization expenses for H1 FY '27 were INR 1,365 million, compared with INR 1,176 million in the same period a year earlier, an increase of 16% that chiefly reflects investments in capacity expansion, North Bangalore included.

Sanjeev Kumar

executive
#10

Finance costs came down 11% year-on-year, landing at INR 775 million versus INR 876 million in H1 FY '26, and that was helped by INR 1,700 million of debt repayments made during the first half of this year. On the bottom line, adjusted PAT — after we normalized the impact of the extraordinary expense — was INR 287 million in H1 FY '27, which works out to 30% growth on a year-on-year basis. Now let me move to our balance sheet. Net debt, excluding capital leases, came in at INR 5,751 million as of September 30, 2026. In the first half we also spent CapEx of INR 1,279 million, mainly toward capacity expansion, material equipment and infrastructure upgrades across our network. Our approach to capital allocation stays disciplined — balancing growth investments with prudent debt management and a continued focus on improving returns on capital. With that, we'd be happy to open the floor for questions. Thank you.

Operator

operator
#11

<<operator_script>> Our first question comes from Aditya Chheda, who is calling in from InCred Asset Management.

Aditya Chheda

analyst
#12

Regarding the price cap exposure, could you take us through the approximate math showing how we get to that mid- to high single-digit EBITDA effect? Then my second question concerns the EPCG provision impact. I believe the overall contingent liability comes to roughly INR 75 crores. So what portion of the additional impact remains, and what does this mean for cash flow?

Manish Mattoo

executive
#13

Thanks, Aditya. Look, on the first item, we need to keep in mind that those 137 drugs that came under the capping make up only a small portion of the total oncology portfolio — the medical oncology portfolio. So that's the first point. It would be hard to go into very fine, minute detail on how we got to that impact. But it's fair to say that on an annualized basis, this will be mid-single digit to high single digit. And more importantly, here's how we're thinking about it: there are a number of levers in play that let us address this over the near to medium term — through trade channel optimization, patient volumes will expand. There will be improved asset utilization. Revenue optimization has kept delivering for us over the last couple of quarters, and that will stay on track. And of course, a number of operating efficiencies will be in play, which will help keep us on track with the earlier estimates that we have continued to provide. But I'd ask Sanjeev to take the EPCG question.

Sanjeev Kumar

executive
#14

We recorded a one-off charge of INR 116 million as a provision tied to that EPCG. After carrying out a thorough review of each of our export obligations, we feel the required provisioning has now been properly reflected in the accounts. As a result, we do not expect any additional material provisions over the near term. I trust that addresses your question.

Aditya Chheda

analyst
#15

Understood. And did that produce a matching cash flow effect, given that in Q1 and Q2 we recorded close to INR 16 crores?

Sanjeev Kumar

executive
#16

Right. So as things stand right now, there’s no cash impact at this point.

Aditya Chheda

analyst
#17

Right. On that first question you answered, Manish, here's what I was after: take those 137 drugs, say they account for 15% or 20% of revenue, and the margins before would have been x, and now they'd be, say, 30%. So any math around that. But if it's possible, otherwise we can talk later.

Manish Mattoo

executive
#18

Sure, Aditya, we can talk about that afterward.

Operator

operator
#19

<<operator_script>> Our following question comes from Devang Patel at Sameeksha Capital.

Devang Patel

analyst
#20

My first question concerns the new Bengaluru Hospital. So it caused some negative effect on margins in this quarter. For how long do you anticipate that drag will persist?

Manish Mattoo

executive
#21

As we mentioned back in Q1, Devang, the revenue ramp-up is proceeding exactly as expected. So revenue, clearly, on a run-rate basis, has improved from Q1 to Q2. And losses are narrowing. In Q1, the loss for the quarter was INR 7.5 crores. In Q2, that has fallen to roughly INR 6 crores. And as we said before, we remain on track to reach EBITDA breakeven by the end of Q4 of this financial year. So nothing has changed on that front. And just to be clear, what we mean is monthly EBITDA breakeven.

Operator

operator
#22

Sumit Gupta from Antique Stockbroking has the next question on the line.

Sumit Gupta

analyst
#23

Regarding the growth piece, I just want to get a clearer picture. Right now, the growth rate has settled at roughly 16%. When might we expect it to get up to around 20% levels, maybe? Hello?

Manish Mattoo

executive
#24

So Sumit, we've been guiding to growth in the mid-teens, paired with EBITDA growth in the high teens to 20%, and we remain on track on that front. Naturally, should any inorganic opportunity come along on top of this — and this is all, of course, organic growth — anything beyond that would add to that growth. But as things stand right now, that guidance is unchanged.

Sumit Gupta

analyst
#25

So about Gujarat — we've basically seen that Gujarat has been performing at double the rate, so when can Gujarat be normalized? And can we expect it to grow to 16%?

Manish Mattoo

executive
#26

My expectation is that Gujarat returns to mid-teens growth by Q4 of this year — that's our anticipation. The reason is that we've intentionally reduced the low-margin business, since we're seeing how curtailing or moderating this revenue growth affects our EBITDA margin expansion. So at the moment I'm not especially worried about that, provided the margin expansion is proceeding according to our plan.

Sumit Gupta

analyst
#27

Okay, so suppose that weren't the situation, and Gujarat were doing what you'd call a solid growth trajectory — what would the normalized growth come out at then? At the moment you're citing 16%, so how much further could that rise from where it stands now?

Manish Mattoo

executive
#28

That's really hard to put a number on, Sumit, honestly. On the whole, I'd say we feel good about hitting the mid-teens revenue growth I mentioned before. And I'd say the majority of our clusters are performing well, which ought to help us reach the target we're working toward.

Sumit Gupta

analyst
#29

Got it. One more thing on the oncology drugs. Of that full set of oncology drugs — call it 100% of them — how many actually fall under the trade margin cap?

Manish Mattoo

executive
#30

Could you say that question again, sir?

Sumit Gupta

analyst
#31

So out of the total oncology drug set that you use for the operation, essentially, how many of those fall under the trade margin cap?

Manish Mattoo

executive
#32

My sense is that most of the drugs now fall within the trade margin cap, with the exception, I believe, of immunotherapy, where margins are in any event below the 30% cap. So in technical terms, all of it now sits under that 30% cap.

Operator

operator
#33

Our following question comes from Gopal Bhatt of Baroda BNP AM, who is on the line.

Gopal Bhatt

analyst
#34

Yeah, so my first question is about the trade margin caps you all brought up. Are you already seeing some effect from them, or does that impact only start now, going forward into this year and '28?

Sanjeev Kumar

executive
#35

So the effect — I mean, any effect we do see is going to show up only in Q — I mean, starting from Q3 onward, but that's because it takes effect in November.

Analyst

analyst
#36

All right, so beginning in Q3 — well, for November specifically, October showed no effect at all. Then across the entire month of November and through December, that impact will become visible.

Sanjeev Kumar

executive
#37

You've got that right.

Analyst

analyst
#38

All right. Let me actually pull back for a moment and pose a wider question to you about regulation as well. I mean, where do you see the — I mean, the government's aims with the — I mean, actually, sorry, this is more something driven by the Supreme Court. But even so, where do you see the wider regulatory picture sort of taking shape? And what do you see as, I mean, an acceptable sort of, say, middle ground or a resolution toward this — for this regulatory in a bit of a tough.

Manish Mattoo

executive
#39

So Gopal, I mean, it's changing, isn't it? The country's needs keep shifting, and the regulatory landscape shifts along with them. There's been substantial investment in health care over the past couple of years, and that brings its own difficulties and consequences for pricing. At the same time, the government is clearly mindful of what serves patients best. So I think this is a work in progress. And I believe the proper balance will be reached via negotiations and consultations, with the government having shown itself open to hearing our point of view and taking a fair position on the matter. I think we've seen that play out as well. But our focus stays on providing high-quality care. And I think that in itself will ensure we achieve the revenue growth and margins we're targeting. So I wouldn't worry too much about it. I think the underlying demand in the system and the need for high-quality care in India will stay strong for many years ahead, and we're very optimistic about that. That's where I'd like to leave it.

Analyst

analyst
#40

So, are there any conversations happening at all? I mean, do you see talks beginning to take shape around an independent regulatory body for the industry?

Manish Mattoo

executive
#41

It's really hard to give you an answer at this point. What I can say is that we have solid representation at present via several associations. This topic has been under discussion for some time, though it's quite difficult to predict whether it might surface within the next 2 years or thereabouts. I honestly have no idea.

Analyst

analyst
#42

All right, understood. And if I could just turn to the financials for a moment. I noticed that your cash and cash equivalents shifted quite a lot during the quarter — sorry, during the half, in the first half of FY '27. So you had INR 543 crores, I believe it's now around INR 130 crores. Could you just — I mean, walk us through where that cash has been used?

Sanjeev Kumar

executive
#43

Right, so there were actually two or three main uses, really. First, we picked up an extra 34% stake in our Vizag operations, and that acquisition took roughly INR 100 crores, INR 150 crores, INR 260 crores. We also paid back INR 170 crores to the banks as part of our debt repayment. So I think those were the three big uses we actually made. And yes, some of the funds went toward our operations too. But those were the two major uses that truly took place.

Analyst

analyst
#44

All right, so that came to roughly INR 320 crores across those two big uses. So if I understand you correctly, you're saying INR 80 crores covers all the general corporate purposes?

Sanjeev Kumar

executive
#45

That's correct.

Manish Mattoo

executive
#46

Gopal, turning to Slide 10 in the earnings presentation, you'll see the full breakdown of how the rights issue proceeds are being used. As Sanjeev noted, INR 150 crores went toward the MG Vizag acquisition, INR 170 crores was allocated to repaying debt, and a further INR 100 crores is for general corporate purposes. Taken together, that covers how the rights proceeds are being utilized.

Operator

operator
#47

<<operator_script>> Our following question comes from Nitin Agarwal of DAM Capital.

Nitin Agarwal

analyst
#48

Regarding the North Bangalore Hospital, what sort of trend line are you seeing for when EBITDA breaks even and for growth after that in the business?

Sanjeev Kumar

executive
#49

Like we mentioned on the previous call, and again today, Manish has confirmed once more that we remain fully on track to reach monthly breakeven — EBITDA breakeven — in Q4 of this year, which is FY '27. So during the January-to-March quarter, we expect to hit breakeven.

Nitin Agarwal

analyst
#50

When you expand that Bangalore facility, does it genuinely benefit the broader business — I mean, does it create any kind of network effect across the whole cluster for you?

Manish Mattoo

executive
#51

Pardon me, could you repeat that?

Nitin Agarwal

analyst
#52

When we scale up the Bangalore facility, does that create a network effect for the cluster? On your end, does it work that way, or is it more appropriate to view it as a stand-alone facility?

Manish Mattoo

executive
#53

No, no, certainly not. In fact, this is working quite effectively for us — since North Bangalore is an entirely distinct micro market. First, I mean, a number of the patients who likely never had access to an HCG facility, many of them can now get that in a new market. Bangalore is basically not a single market; it's 5 separate markets. So I'm pleased that we now have another modern hospital in that new micro market. And when you look at the growth as North Bangalore comes up, it has actually created a positive spin-off for our KR Center of Excellence too. It is ramping up more quickly than last year. Revenue growth has been quicker than last year. We used to average 16%, 17%, but this year, growth has been 20% plus for that hospital. So I believe it definitely is going to — it is helping us through the network synergy effect. And then, naturally, we gain the advantage of utilizing consultants across both hospitals. Empanelment has been coming in faster. The sales and marketing efforts are well synergized. So there are plenty of benefits.

Nitin Agarwal

analyst
#54

Okay, regarding the ARPP growth you're seeing in the South cluster — 14% ARPP growth — you did mention the greater use of robotic surgeries and so on. But is there anything else worth highlighting, because that's a pretty staggering increase showing up in the ARPP? And how should we think about ARPP growth in this cluster going forward?

Manish Mattoo

executive
#55

I think the rise in ARPP, as you correctly pointed out, is driven by more robotic surgeries, but it has also come from high-end radiation therapies as well as high-end theragnostic work, which the Bangalore center is known for, along with the payer mix shift that we have observed. So I think all these factors are coming together, which has been our thesis from the very beginning. And as we see that impact across the network, we'll see ARPPs rise and improve gradually. Looking ahead as well, I think I reaffirm the guidance we have provided on ARPPs at least ahead of inflation — that's what we should — that's what we are aiming for.

Nitin Agarwal

analyst
#56

Since you brought that up, when you look at the ARPP increase, clearly it reflects a mix of additional high-end procedures along with some rationalization on the payer mix side. On that second piece — I believe that's something you've flagged across a number of regions — could you walk through some of the thinking behind the payer mix rationalization and how that actually unfolds going forward?

Manish Mattoo

executive
#57

I'd say the rationalization of payer mix comes from several things happening at once. In my view, it's better infrastructure, along with the right clinical talent — people we've been bringing on board and will keep bringing on board. It's also our emphasis on organ-specific work, which is what HCG is known for. Then there's clinical differentiation that shows up through clinical outcomes and our tumor board-driven clinical protocols — something we're known for — plus getting that message across to patients through a stronger brand and stronger marketing efforts. And naturally, there's the robust sales and marketing activation on the ground. I think it's all of those activities, carried out consistently with real focus on execution, that is producing the payer mix shift you've observed.

Nitin Agarwal

analyst
#58

Is it reasonable to think that much of this — I mean, as a result of the payer mix shift we're doing broadly, or that seems to be occurring broadly — should probably result in some decrease in the corporate portion of the business?

Manish Mattoo

executive
#59

Not corporate-only, no. Actually, I'd say it fits cash and insurance too, though corporate is a component as well. That's another area where I believe we have room to improve. Still, my view is that it applies across cash, insurance, and corporate business. The levers are really the same in terms of impact, since all of these are favorable payers for us.

Nitin Agarwal

analyst
#60

Am I able to go a bit further? Does this exercise we're doing — I mean, are we giving up some volumes here — are we allowing certain volumes to slip away during this process?

Manish Mattoo

executive
#61

Well, yes — as I mentioned in my commentary earlier, take Gujarat as an example: we've intentionally reduced our reliance on low-margin payers and so on. Naturally, from time to time there will be, I'd say, some moderation in volumes as we work toward serving better payers, but that's a deliberate decision on our part. At the same time, it's not as though we can simply exit a payer overnight. So this happens gradually, with patients' interests kept in mind as well. But yes, in certain markets, during certain quarters, it could lead to volumes moderating.

Sanjeev Kumar

executive
#62

On the institutional business side, we saw moderation in volume—not across the board.

Manish Mattoo

executive
#63

To reiterate what I mentioned, take Q2 as an example: non-institutional growth came in at 21%, while institutional growth was 5%. So clearly, that — I hope that clears up your question.

Operator

operator
#64

Our next follow-up question comes from Devang Patel at Sameeksha Capital.

Devang Patel

analyst
#65

I got disconnected a bit ago. My remaining question concerns how we ought to view the first half <<inaudible>> when normalized, apart from that INR 165 crores payout? Anything else <<inaudible>>

Sanjeev Kumar

executive
#66

Is it really the remaining 15% stake in Vizag that you're referring to buying?

Devang Patel

analyst
#67

Right. So the operating cash flow we reported was INR 139 crores <<inaudible>> 64%, and that's below what you've achieved previously.

Sanjeev Kumar

executive
#68

Okay, so if you look closely — you're correct that CFO to EBITDA conversion sits at roughly 54%, versus more than 80% in the same quarter a year ago — in H1. Essentially, when you dig into it, there are two factors here. First, we received close to INR 36 crores from the AP government under the Aarogyasri scheme, and right now that's being reflected as part of borrowings. That's one piece. Second, the credit period with one of our key suppliers has shifted — it increased by about 30 days, having previously stood at 90 days. If you really examine these two items, the normalized conversion would land approximately in that same range. Another element is that in last year's H1, there was a tax expense. If you look at it, a deferred tax asset was recognized amounting to nearly INR 9.6 crores, while in this quarter there's been a tax expense of roughly INR 30 crores. So those are the three or four main reasons why this conversion comes in at 44%, as it appears.

Devang Patel

analyst
#69

And sir, the INR 155 crores payout also had an effect on OCF, because otherwise it would have risen from your provisions?

Sanjeev Kumar

executive
#70

Which INR 155 crores — sorry, I'm not sure which INR 155 crores you mean?

Devang Patel

analyst
#71

Regarding what you're paying for the Vizag acquisition's remaining 34% stake — would that be <<inaudible>>?

Manish Mattoo

executive
#72

No. So that INR 155 crores has definitely had an effect on the total cash flow. But like we mentioned at the start, this was — we had done a rights issue before that, which came to roughly INR 400 crores. And this INR 150 crores came out of the money from that rights issue. So the operating cash flow may not be affected by it.

Devang Patel

analyst
#73

But looking ahead, would you anticipate that returning to the usual 85% on an annual basis? <<inaudible>>

Sanjeev Kumar

executive
#74

Yeah, we're definitely keeping an eye on the improvement in cash flow from operations, because a number of the items I mentioned really are onetime in nature. And those will certainly settle down, and that should help drive better cash flows.

Devang Patel

analyst
#75

Alright, my second question concerns the volumes for Q2 of last year. Some reclassification has now been carried out. Is that happening because the fertility business is leaving the base? Or was there another adjustment involved?

Operator

operator
#76

Sir, we can’t hear you. <<inaudible>>

Manish Mattoo

executive
#77

Right. So every one of the operational metrics leaves out the Milann facility. That means you won't find any reclassification or adjustment showing up in those operational metrics. However, when it comes to all the P&L metrics — revenue and EBITDA — the presentation reports them with the Milann facility excluded, on a like-for-like comparison basis.

Operator

operator
#78

<<operator_script>> Our following question comes from Sumit Gupta of Antique.

Sumit Gupta

analyst
#79

Just one question, sir. For H1 FY'27, what tax rate should we use?

Manish Mattoo

executive
#80

We’re able to continue. My apologies—our end dropped the connection to the call.

Sumit Gupta

analyst
#81

Do you want me to go over that again?

Manish Mattoo

executive
#82

Yes, Sumit, please go ahead with your question.

Sumit Gupta

analyst
#83

What tax rate ought we to use for FY'27, and then afterward for the <<inaudible>>?

Manish Mattoo

executive
#84

Could you repeat your question, please?

Sumit Gupta

analyst
#85

What tax rate should we use for FY'27 moving forward?

Manish Mattoo

executive
#86

Right. So for the near term, at this point we'll need to plan around a tax rate of roughly 35% to 40%. That said, I do think that after a year or so, it ought to settle at close to 30% to 35%.

Operator

operator
#87

Now we'll take our next follow-up question, coming from Gopal Bhatt at Baroda BNP AM.

Gopal Bhatt

analyst
#88

I just want to check one thing with you. When we look at the pattern of ARPP growth and volume growth across your clusters, it appears that the South cluster is somewhat more mature, since there you're growing mainly by raising the complexity of the procedures and so on, whereas in West and East you're seeing volume growth that is much stronger relative to ARPP. So those seem to be relatively newer clusters for you, and ones where you're still gaining on volumes. Is that a fair assessment?

Manish Mattoo

executive
#89

Naturally, how old the hospitals are matters, along with the technology investments we've put in and how mature the clinical programs have become — and we're starting to replicate those programs across the other clusters too. Especially in the East cluster and now in Maharashtra, we're seeing volume growth that's very encouraging. And given what we've learned from the South cluster, I think we should end up in a comparable position across all the remaining clusters. That said, the assessment you made is a fair one.

Analyst

analyst
#90

All right, understood. Sorry — just a small bookkeeping-type question. Regarding the HCG provisions you've recorded, I'd like to grasp why the company qualifies for them. From my understanding, you're taking advantage of some import duty exemptions tied to export obligations, correct? So does this connect to the Kenya operation, or on what basis do we qualify?

Sanjeev Kumar

executive
#91

No, so this isn't just tied to the Kenya operations. Under government policy, if you have eligible export proceeds, then whenever you import anything, you can — you qualify for the reduced customs duty. And when the government grants that customs duty benefit, then per the policy, you — you must generate 6x export proceeds within a certain period. And really, that's how the policy works. This policy covers health care companies too. So the international revenue that comes in through the MVT process counts as export earnings.

Analyst

analyst
#92

So, MVT also helps you qualify for this exemption, is that right?

Sanjeev Kumar

executive
#93

You've got it.

Analyst

analyst
#94

And all right. So you've essentially gone back over it — I mean, what's your revised view looking at the year?

Sanjeev Kumar

executive
#95

Right. So we went through a thorough review of everything — what work we needed to carry out and how much we anticipate it will take, based on how we see things right now. And in fact, under our conservative accounting policies, we chose to set up a provision reflecting how the situation appears. Given the unrest in the Middle East and Bangladesh, which has been going on for some time, our projections have genuinely been affected relative to the actual figures. That's why this one.

Manish Mattoo

executive
#96

We made the decision to set aside a provision.

Analyst

analyst
#97

All right, that's fair. That's fair. So what would the MVT contribution have been — say, before all of this — in FY '26? And this year, in the first half, what would the MVT contribution be?

Sanjeev Kumar

executive
#98

MVT for us as a business is expanding at a rate of 20%-25%. The prior year, that figure stood at roughly 3%. In the current year, it's going to land somewhere in the range of 4% to 5% of total revenue.

Analyst

analyst
#99

All right. So even with the geopolitical disruptions, you still managed to raise the share in the first half.

Sanjeev Kumar

executive
#100

Revenue has been growing. EPCG is a separate matter, since it's what I'd call a retrospective deficit—you can't make that up in only 1 or 2 years, correct? That's where the gap sits.

Operator

operator
#101

<<operator_script>> Our next follow-up question comes from Devang Patel at Sameeksha Capital.

Devang Patel

analyst
#102

Sir, as a follow-up regarding the effect on trade margin, since you do have an impact on revenues, does our guidance for revenue growth and margins for this year remain — does it still hold?

Sanjeev Kumar

executive
#103

My sense is that there could be a minor effect for perhaps a quarter or two. Yet, as we noted before, on an annualized basis it comes to a mid- to high single-digit impact. Going forward, though, I don't expect any effect at all.

Devang Patel

analyst
#104

Is that mid- to high single-digit effect something we'd see in one quarter, or does it stretch across the next four quarters?

Sanjeev Kumar

executive
#105

So for this year, when you look at it on an annualized basis.

Manish Mattoo

executive
#106

What we're doing here is simply offering you a read on how things stand as of today. On an annualized basis, then, it's likely to land in the mid- to high single digit. For the remaining half of this fiscal year, though, naturally it would scale down proportionally — something in the low mid-single-digit range. Then as we move ahead into FY '28 and '29, our expectation is that we can stay on a mid-teen revenue growth path, paired with EBITDA growth in the high teens, while margins keep improving.

Devang Patel

analyst
#107

And does that bring margins back up to where they were on the earlier trajectory? Or does it set the base lower instead?

Manish Mattoo

executive
#108

Honestly, I don't see any material impact, and from FY '28 onward we ought to be able to catch up.

Operator

operator
#109

That brings us to the final question, everyone. That wraps up the Q&A portion. I'll now turn the conference back over to management for some closing remarks. Thanks, and the floor is yours, sir.

Manish Mattoo

executive
#110

Thanks, and I appreciate all of you spending part of your day with us. From everyone on the HCG team, I want to wish each of you and your loved ones a joyful, secure and successful Diwali, and we can't wait to connect with you once more in the next quarter. Many thanks, and enjoy a wonderful weekend.

Operator

operator
#111

Appreciate you, members of the management team. That brings us to the close of this conference on behalf of Healthcare Global Enterprises Limited. Thanks to all of you for being with us today; you're welcome to disconnect your lines now, and we wish each of you a happy Diwali.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete HealthCare Global Enterprises Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to HealthCare Global Enterprises Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in HealthCare Global Enterprises Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.